Neuropathic Pain in Rheumatoid Arthritis Linked to Vitamin D Deficiency
Among patients with serum vitamin D levels <20 ng/mL, the prevalence of NP was 5.8 times higher than in patients with vitamin D levels ≥30 ng/mL.
Year In Review Rheumatoid Arthritis
Biosimilar Cyltezo Gets FDA Approval for Multiple Indications
This marks the second approval of a biosimilar for adalimumab.
Oral Contraceptives May Reduce Rheumatoid Arthritis Risk
The researchers found that ever and past OC users had a reduced risk of anticitrullinated protein antibodies (ACPA)-positive RA compared with never users.
Certain Occupations May Increase the Risk for Rheumatoid Arthritis
Assistant nurses and attendants had a moderately increased risk of ACPA+ RA among women (odds ratio, 1.3; 95% CI, 1.1 to 1.6), while no occupations correlated significantly with ACPA− RA.
Case: Hand Transplant Patient Develops Rheumatoid Arthritis
“To our knowledge, this is the first report of rheumatoid arthritis in a hand transplant recipient,” the authors write. “Whether it constitutes an atypical transplant rejection is unclear.”
Fish Consumption and RA Symptoms: What’s the Link?
Researchers suggest most varieties of fish may play a role in controlling symptoms
Opioid Use Patterns Among RA Patients Examined
The authors concluded that “rheumatologists and other clinicians caring for patients with RA face a significant dilemma precisely because the options for care of pain remain problematic.”
Guidelines Address Peri-Op Management of Antirheumatic Drugs
The guidelines address perioperative use of antirheumatic drug therapy for adults with rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, or systemic lupus erythematosus undergoing elective THA or TKA.
Early Treatment of ‘Pre-RA’ Patients May Reduce Risk of Rheumatoid Arthritis
Study authors identified two congress abstracts and nine randomized controlled trials: eight of which were related to undifferentiated arthritis, and one which was related to very early RA.
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
